F1 PharmaS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2019-08-06
Share capital
1 669 800,00 PLN
Activity description

F1 Pharma provides research and development services for the pharmaceutical industry. The company works in pharmaceutical technology, analytics, stability testing, and quality assurance. It also carries out comprehensive development of medicinal products, including new drug forms.

Registered address
ul. Profesora Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Website
f1pharma.plWebsite active
Email
Email address current
Phone
Electronic delivery address
AE:PL-17662-97685-DAFHE-10

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 272.11kMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 25.45kMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 238.76kMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 203.79kMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 2010-11-17. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Apr 4, 2024Shareholders' meeting convened
Dec 11, 2020Commercial Companies Code notice
Nov 26, 2020Commercial Companies Code notice
Oct 26, 2020Commercial Companies Code notice
Oct 9, 2020Commercial Companies Code notice

Public aid

9 public aid cases recorded, with a total value of $1,035,930.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$79,573
Aid for research and development projects: industrial research
$488.6K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$93,524

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Mirosław Marek Strózik – President of the Management Board

Manner of representation

The company is represented by two members of the management board acting jointly.

Supervisory board

Krzysztof Flak – Supervisory Board Member
Piotr Pątko – Supervisory Board Member
Paweł Szydłowski – Supervisory Board Member

Beneficial owners

Person

Competitors

Name
PoltregS.A.
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.
Pexon Polandsp. z o.o.
LideoS.A.
Ampliconsp. z o.o.

FAQ

Last updated: 2026-10-03